Literature DB >> 24687493

Assessment of Mycobacterium tuberculosis pantothenate kinase vulnerability through target knockdown and mechanistically diverse inhibitors.

B K Kishore Reddy1, Sudhir Landge1, Sudha Ravishankar2, Vikas Patil1, Vikas Shinde1, Subramanyam Tantry1, Manoj Kale1, Anandkumar Raichurkar1, Sreenivasaiah Menasinakai1, Naina Vinay Mudugal2, Anisha Ambady2, Anirban Ghosh2, Ragadeepthi Tunduguru2, Parvinder Kaur2, Ragini Singh3, Naveen Kumar4, Sowmya Bharath4, Aishwarya Sundaram2, Jyothi Bhat2, Vasan K Sambandamurthy2, Christofer Björkelid5, T Alwyn Jones5, Kaveri Das2, Balachandra Bandodkar1, Krishnan Malolanarasimhan1, Kakoli Mukherjee2, Vasanthi Ramachandran6.   

Abstract

Pantothenate kinase (PanK) catalyzes the phosphorylation of pantothenate, the first committed and rate-limiting step toward coenzyme A (CoA) biosynthesis. In our earlier reports, we had established that the type I isoform encoded by the coaA gene is an essential pantothenate kinase in Mycobacterium tuberculosis, and this vital information was then exploited to screen large libraries for identification of mechanistically different classes of PanK inhibitors. The present report summarizes the synthesis and expansion efforts to understand the structure-activity relationships leading to the optimization of enzyme inhibition along with antimycobacterial activity. Additionally, we report the progression of two distinct classes of inhibitors, the triazoles, which are ATP competitors, and the biaryl acetic acids, with a mixed mode of inhibition. Cocrystallization studies provided evidence of these inhibitors binding to the enzyme. This was further substantiated with the biaryl acids having MIC against the wild-type M. tuberculosis strain and the subsequent establishment of a target link with an upshift in MIC in a strain overexpressing PanK. On the other hand, the ATP competitors had cellular activity only in a M. tuberculosis knockdown strain with reduced PanK expression levels. Additionally, in vitro and in vivo survival kinetic studies performed with a M. tuberculosis PanK (MtPanK) knockdown strain indicated that the target levels have to be significantly reduced to bring in growth inhibition. The dual approaches employed here thus established the poor vulnerability of PanK in M. tuberculosis.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24687493      PMCID: PMC4068421          DOI: 10.1128/AAC.00140-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Expression of the pyrG gene determines the pool sizes of CTP and dCTP in Lactococcus lactis.

Authors:  Casper M Jørgensen; Karin Hammer; Peter R Jensen; Jan Martinussen
Journal:  Eur J Biochem       Date:  2004-06

2.  Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.

Authors:  Vasan K Sambandamurthy; Steven C Derrick; Kripa V Jalapathy; Bing Chen; Robert G Russell; Sheldon L Morris; William R Jacobs
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

3.  Pristinamycin-inducible gene regulation in mycobacteria.

Authors:  Francesca Forti; Andrea Crosta; Daniela Ghisotti
Journal:  J Biotechnol       Date:  2009-02-13       Impact factor: 3.307

4.  Depletion of antibiotic targets has widely varying effects on growth.

Authors:  Jun-Rong Wei; Vidhya Krishnamoorthy; Kenan Murphy; Jee-Hyun Kim; Dirk Schnappinger; Tom Alber; Christopher M Sassetti; Kyu Y Rhee; Eric J Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-22       Impact factor: 11.205

5.  Essentiality and functional analysis of type I and type III pantothenate kinases of Mycobacterium tuberculosis.

Authors:  Disha Awasthy; Anisha Ambady; Jyothi Bhat; Gulebahar Sheikh; Sudha Ravishankar; Venkita Subbulakshmi; Kakoli Mukherjee; Vasan Sambandamurthy; Umender Sharma
Journal:  Microbiology       Date:  2010-06-24       Impact factor: 2.777

Review 6.  Scaling up interventions to achieve global tuberculosis control: progress and new developments.

Authors:  Mario Raviglione; Ben Marais; Katherine Floyd; Knut Lönnroth; Haileyesus Getahun; Giovanni B Migliori; Anthony D Harries; Paul Nunn; Christian Lienhardt; Steve Graham; Jeremiah Chakaya; Karin Weyer; Stewart Cole; Stefan H E Kaufmann; Alimuddin Zumla
Journal:  Lancet       Date:  2012-05-19       Impact factor: 79.321

7.  Metabolic resistance: the protection of enzymes against drugs which are tight-binding inhibitors by the accumulation of substrate.

Authors:  R I Christopherson; R G Duggleby
Journal:  Eur J Biochem       Date:  1983-08-01

8.  From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways.

Authors:  Svetlana Y Gerdes; Michael D Scholle; Mark D'Souza; Axel Bernal; Mark V Baev; Michael Farrell; Oleg V Kurnasov; Matthew D Daugherty; Faika Mseeh; Boris M Polanuyer; John W Campbell; Shubha Anantha; Konstantin Y Shatalin; Shamim A K Chowdhury; Michael Y Fonstein; Andrei L Osterman
Journal:  J Bacteriol       Date:  2002-08       Impact factor: 3.490

9.  Acyl carrier protein is a cellular target for the antibacterial action of the pantothenamide class of pantothenate antimetabolites.

Authors:  Yong-Mei Zhang; Matthew W Frank; Kristopher G Virga; Richard E Lee; Charles O Rock; Suzanne Jackowski
Journal:  J Biol Chem       Date:  2004-09-30       Impact factor: 5.157

10.  A kinetic platform for in silico modeling of the metabolic dynamics in Escherichia coli.

Authors:  Aditya Barve; Anvita Gupta; Suresh M Solapure; Ansu Kumar; Vasanthi Ramachandran; Kothandaraman Seshadri; Shireen Vali; Santanu Datta
Journal:  Adv Appl Bioinform Chem       Date:  2010-12-07
View more
  13 in total

Review 1.  Mycobacterium tuberculosis in the Face of Host-Imposed Nutrient Limitation.

Authors:  Michael Berney; Linda Berney-Meyer
Journal:  Microbiol Spectr       Date:  2017-06

2.  A d-Phenylalanine-Benzoxazole Derivative Reveals the Role of the Essential Enzyme Rv3603c in the Pantothenate Biosynthetic Pathway of Mycobacterium tuberculosis.

Authors:  Michael J Pepi; Shibin Chacko; Gary M Marqus; Vinayak Singh; Zhe Wang; Kyle Planck; Ryan T Cullinane; Penchala N Meka; Deviprasad R Gollapalli; Thomas R Ioerger; Kyu Y Rhee; Gregory D Cuny; Helena I M Boshoff; Lizbeth Hedstrom
Journal:  ACS Infect Dis       Date:  2022-01-11       Impact factor: 5.578

3.  Targeting Mycobacterium tuberculosis CoaBC through Chemical Inhibition of 4'-Phosphopantothenoyl-l-cysteine Synthetase (CoaB) Activity.

Authors:  Joanna C Evans; Dinakaran Murugesan; John M Post; Vitor Mendes; Zhe Wang; Navid Nahiyaan; Sasha L Lynch; Stephen Thompson; Simon R Green; Peter C Ray; Jeannine Hess; Christina Spry; Anthony G Coyne; Chris Abell; Helena I M Boshoff; Paul G Wyatt; Kyu Y Rhee; Tom L Blundell; Clifton E Barry; Valerie Mizrahi
Journal:  ACS Infect Dis       Date:  2021-05-03       Impact factor: 5.084

4.  Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform.

Authors:  Jeremy M Rock; Forrest F Hopkins; Alejandro Chavez; Marieme Diallo; Michael R Chase; Elias R Gerrick; Justin R Pritchard; George M Church; Eric J Rubin; Christopher M Sassetti; Dirk Schnappinger; Sarah M Fortune
Journal:  Nat Microbiol       Date:  2017-02-06       Impact factor: 17.745

5.  Characterization and validation of Entamoeba histolytica pantothenate kinase as a novel anti-amebic drug target.

Authors:  Arif Nurkanto; Ghulam Jeelani; Takehiro Yamamoto; Yoshiko Naito; Takako Hishiki; Mihoko Mori; Makoto Suematsu; Kazuro Shiomi; Tetsuo Hashimoto; Tomoyoshi Nozaki
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-03-01       Impact factor: 4.077

Review 6.  The application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosis.

Authors:  Joanna C Evans; Valerie Mizrahi
Journal:  Front Microbiol       Date:  2015-08-04       Impact factor: 5.640

7.  Essentiality Assessment of Cysteinyl and Lysyl-tRNA Synthetases of Mycobacterium smegmatis.

Authors:  Sudha Ravishankar; Anisha Ambady; Rayapadi G Swetha; Anand Anbarasu; Sudha Ramaiah; Vasan K Sambandamurthy
Journal:  PLoS One       Date:  2016-01-21       Impact factor: 3.240

8.  Validation of CoaBC as a Bactericidal Target in the Coenzyme A Pathway of Mycobacterium tuberculosis.

Authors:  Joanna C Evans; Carolina Trujillo; Zhe Wang; Hyungjin Eoh; Sabine Ehrt; Dirk Schnappinger; Helena I M Boshoff; Kyu Y Rhee; Clifton E Barry; Valerie Mizrahi
Journal:  ACS Infect Dis       Date:  2016-10-05       Impact factor: 5.084

9.  A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK.

Authors:  Laurent R Chiarelli; Giorgia Mori; Beatrice Silvia Orena; Marta Esposito; Thomas Lane; Ana Luisa de Jesus Lopes Ribeiro; Giulia Degiacomi; Júlia Zemanová; Sára Szádocka; Stanislav Huszár; Zuzana Palčeková; Marcello Manfredi; Fabio Gosetti; Joël Lelièvre; Lluis Ballell; Elena Kazakova; Vadim Makarov; Emilio Marengo; Katarina Mikusova; Stewart T Cole; Giovanna Riccardi; Sean Ekins; Maria Rosalia Pasca
Journal:  Sci Rep       Date:  2018-02-16       Impact factor: 4.379

Review 10.  Multitargeting Compounds: A Promising Strategy to Overcome Multi-Drug Resistant Tuberculosis.

Authors:  Giovanni Stelitano; José Camilla Sammartino; Laurent Roberto Chiarelli
Journal:  Molecules       Date:  2020-03-09       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.